Table 1 Antimyeloma RWCP treatments during index and subsequent LOT.

From: LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis)

Treatment, n (%)a

Index LOT (N = 248)

1st Subsequent LOT (n = 152)

2nd Subsequent LOT (n = 74)

3rd Subsequent LOT (n = 42)

≥4th Subsequent LOT (n = 17)

Glucocorticoids

227 (91.5)

107 (70.4)

47 (63.5)

23 (54.8)

9 (52.9)

PI

135 (54.4)

53 (34.9)

24 (32.4)

9 (21.4)

8 (47.1)

 Carfilzomib

63 (25.4)

22 (14.5)

11 (14.9)

3 (7.1)

3 (17.6)

 Bortezomib

50 (20.2)

24 (15.8)

10 (13.5)

5 (11.9)

6 (35.3)

 Ixazomib

22 (8.9)

7 (4.6)

3 (4.1)

1 (2.4)

1 (5.9)

IMiD

121 (48.8)

51 (33.6)

17 (23)

10 (23.8)

7 (41.2)

 Pomalidomide

74 (29.8)

30 (19.7)

7 (9.5)

6 (14.3)

4 (23.5)

 Lenalidomide

36 (14.5)

9 (5.9)

5 (6.8)

3 (7.1)

5 (29.4)

 Thalidomide

11 (4.4)

11 (7.2)

5 (6.8)

1 (2.4)

1 (5.9)

 Iberdomide

0 (0)

1 (0.7)

0 (0)

0 (0)

0 (0)

Alkylating agents

108 (43.5)

68 (44.7)

29 (39.2)

13 (31)

5 (29.4)

 Cyclophosphamide

80 (32.3)

43 (28.3)

17 (23)

7 (16.7)

4 (23.5)

 Bendamustine

16 (6.5)

14 (9.2)

6 (8.1)

2 (4.8)

0 (0)

 Melphalan

14 (5.6)

13 (8.6)

6 (8.1)

4 (9.5)

0 (0)

 Carmustine

1 (0.4)

1 (0.7)

1 (1.4)

1 (2.4)

0 (0)

 Other

1 (0.4)

0 (0)

0 (0)

1 (2.4)

0 (0)

 Melflufen

0 (0)

0 (0)

1 (1.4)

0 (0)

1 (5.9)

Anti-CD38 mAb

24 (9.7)

16 (10.5)

5 (6.8)

11 (26.2)

7 (41.2)

 Daratumumab

23 (9.3)

13 (8.6)

4 (5.4)

5 (11.9)

6 (35.3)

 Isatuximab

1 (0.4)

3 (2)

1 (1.4)

6 (14.3)

2 (11.8)

BCMA-targeted therapies

7 (2.8)

24 (15.8)

21 (28.4)

10 (23.8)

7 (41.2)

 CAR-T

0 (0)

0 (0)

2 (2.7)

0 (0)

1 (5.9)

 Bispecific antibody

0 (0)

5 (3.3)

2 (2.7)

0 (0)

4 (23.5)

 Antibody-drug conjugate

7 (2.8)

19 (12.5)

17 (23)

10 (23.8)

3 (17.6)

Anthracyclines

21 (8.5)

8 (5.3)

7 (9.5)

4 (9.5)

2 (11.8)

Topoisomerase inhibitor

17 (6.9)

6 (3.9)

3 (4.1)

1 (2.4)

0 (0)

Histone deacetylase inhibitor

12 (4.8)

6 (3.9)

0 (0)

0 (0)

0 (0)

Anti-SLAMF7 mAb

9 (3.6)

7 (4.6)

0 (0)

1 (2.4)

2 (11.8)

BCL-2 inhibitor

6 (2.4)

3 (2)

2 (2.7)

2 (4.8)

1 (5.9)

Selective inhibitor of nuclear export

2 (0.8)

11 (7.2)

3 (4.1)

3 (7.1)

4 (23.5)

Other

19 (7.67)

9 (5.9)

7 (9.5)

4 (9.5)

4 (23.5)

  1. BCMA B-cell maturation antigen, Bcl B-cell lymphoma, CAR chimeric antigen receptor, IMiD immunomodulatory drug, LOT line of therapy, mAb monoclonal antibody, RWCP real-world clinical practice, PI proteasome inhibitor, SLAM signaling lymphocytic activation molecule.
  2. aPatients can be counted in >1 drug group.
Back to article page